GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicofarma Biotech SA (WAR:MDB) » Definitions » EV-to-EBIT

Medicofarma Biotech (WAR:MDB) EV-to-EBIT : -54.93 (As of May. 29, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Medicofarma Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medicofarma Biotech's Enterprise Value is zł56.91 Mil. Medicofarma Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was zł-1.04 Mil. Therefore, Medicofarma Biotech's EV-to-EBIT for today is -54.93.

The historical rank and industry rank for Medicofarma Biotech's EV-to-EBIT or its related term are showing as below:

WAR:MDB' s EV-to-EBIT Range Over the Past 10 Years
Min: -1265.94   Med: -29.36   Max: 99999999.99
Current: -54.93

During the past 13 years, the highest EV-to-EBIT of Medicofarma Biotech was 99999999.99. The lowest was -1265.94. And the median was -29.36.

WAR:MDB's EV-to-EBIT is ranked worse than
100% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.885 vs WAR:MDB: -54.93

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Medicofarma Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was zł64.52 Mil. Medicofarma Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was zł-1.04 Mil. Medicofarma Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1.61%.


Medicofarma Biotech EV-to-EBIT Historical Data

The historical data trend for Medicofarma Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicofarma Biotech EV-to-EBIT Chart

Medicofarma Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.13 -6.63 -22.98 -571.71 -49.28

Medicofarma Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.28 -35.57 -36.05 -42.64 -62.28

Competitive Comparison of Medicofarma Biotech's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medicofarma Biotech's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medicofarma Biotech's EV-to-EBIT falls into.



Medicofarma Biotech EV-to-EBIT Calculation

Medicofarma Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=56.906/-1.036
=-54.93

Medicofarma Biotech's current Enterprise Value is zł56.91 Mil.
Medicofarma Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-1.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicofarma Biotech  (WAR:MDB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Medicofarma Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-1.036/64.519385
=-1.61 %

Medicofarma Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was zł64.52 Mil.
Medicofarma Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-1.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicofarma Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Medicofarma Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicofarma Biotech (WAR:MDB) Business Description

Traded in Other Exchanges
N/A
Address
ul. Soko?owska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.